Oral Metal-Free Melanin Nanozymes for Natural and Durable Targeted Treatment of Inflammatory Bowel Disease (IBD)
- PMID: 36760016
- DOI: 10.1002/smll.202207350
Oral Metal-Free Melanin Nanozymes for Natural and Durable Targeted Treatment of Inflammatory Bowel Disease (IBD)
Abstract
Oral antioxidant nanozymes bring great promise for inflammatory bowel disease (IBD) treatment. To efficiently eliminate reactive oxygen species (ROS), various metal-based nanozymes have been developed for the treatment of IBD but their practical applications are seriously impaired by unstable ROS-eliminating properties and potential metal ion leakage in the digestive tract. Here, the authors for the first time propose metal-free melanin nanozymes (MeNPs) with excellent gastrointestinal stability and biocompatibility as a favorable therapy strategy for IBD. Moreover, MeNPs have extremely excellent natural and long-lasting characteristics of targeting IBD lesions. In view of the dominant role of ROS in IBD, the authors further reveal that oral administration of MeNPs can greatly alleviate the six major pathological features of IBD: oxidative stress, endoplasmic reticulum stress, apoptosis, inflammation, gut barrier disruption, and gut dysbiosis. Overall, this strategy highlights the great clinical application prospects of metal-free MeNPs via harnessing ROS scavenging at IBD lesions, offering a paradigm for antioxidant nanozyme in IBD or other inflammatory diseases.
Keywords: anti-inflammatory; inflammatory bowel diseases; melanin; nanozymes; reactive oxygen species (ROS) scavenger; ulcerative colitis.
© 2023 Wiley-VCH GmbH.
Similar articles
-
Orally Deliverable Microalgal-Based Carrier with Selenium Nanozymes for Alleviation of Inflammatory Bowel Disease.ACS Appl Mater Interfaces. 2024 Sep 25;16(38):50212-50228. doi: 10.1021/acsami.4c08020. Epub 2024 Sep 12. ACS Appl Mater Interfaces. 2024. PMID: 39266250
-
Rational Design of Orally Administered Cascade Nanozyme for Inflammatory Bowel Disease Therapy.Adv Mater. 2023 Nov;35(44):e2304967. doi: 10.1002/adma.202304967. Epub 2023 Sep 21. Adv Mater. 2023. PMID: 37608768
-
Zero-Valence Selenium-Enriched Prussian Blue Nanozymes Reconstruct Intestinal Barrier against Inflammatory Bowel Disease via Inhibiting Ferroptosis and T Cells Differentiation.Adv Healthc Mater. 2023 May;12(12):e2203160. doi: 10.1002/adhm.202203160. Epub 2023 Jan 30. Adv Healthc Mater. 2023. PMID: 36651877
-
Wielding the double-edged sword: Redox drug delivery systems for inflammatory bowel disease.J Control Release. 2023 Jun;358:510-540. doi: 10.1016/j.jconrel.2023.05.007. Epub 2023 May 15. J Control Release. 2023. PMID: 37169178 Review.
-
Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease.Front Endocrinol (Lausanne). 2023 Aug 28;14:1217165. doi: 10.3389/fendo.2023.1217165. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37701897 Free PMC article. Review.
Cited by
-
Enhanced Codelivery of Gefitinib and Azacitidine for Treatment of Metastatic-Resistant Lung Cancer Using Biodegradable Lipid Nanoparticles.Materials (Basel). 2023 Jul 30;16(15):5364. doi: 10.3390/ma16155364. Materials (Basel). 2023. PMID: 37570067 Free PMC article.
-
2D-nanomaterials for AKI treatment.Front Bioeng Biotechnol. 2023 Mar 9;11:1159989. doi: 10.3389/fbioe.2023.1159989. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 36970615 Free PMC article. Review.
-
Artificial mucus layer formed in response to ROS for the oral treatment of inflammatory bowel disease.Sci Adv. 2024 Jul 26;10(30):eado8222. doi: 10.1126/sciadv.ado8222. Epub 2024 Jul 26. Sci Adv. 2024. PMID: 39058786 Free PMC article.
-
Pectinase responsive nanoplatform for oral targeted delivery 5-aminosalicylic acid and zinc coordination driven nanozyme in inflammatory bowel disease treatment.Int J Pharm X. 2025 Jul 16;10:100362. doi: 10.1016/j.ijpx.2025.100362. eCollection 2025 Dec. Int J Pharm X. 2025. PMID: 40747109 Free PMC article.
-
Curcumin@Fe/Tannic Acid Complex Nanoparticles for Inflammatory Bowel Disease Treatment.ACS Omega. 2024 Mar 14;9(12):14316-14322. doi: 10.1021/acsomega.3c10214. eCollection 2024 Mar 26. ACS Omega. 2024. PMID: 38559927 Free PMC article.
References
-
- K. Clarke, J. Chintanaboina, Clin. Rev. Allergy Immunol. 2019, 57, 179.
-
- Explore results from the 2019 Global Burden of Disease (GBD) study[EB/OL], https://vizhub.healthdata.org/gbd-results/ (accessed: November 2022).
-
- H. Wang, K. M. Abbas, M. Abbasifard, M. Abbasi-Kangevari, H. Abbastabar, F. Abd-Allah, A. Abdelalim, H. Abolhassani, L. G. Abreu, M. R. M. Abrigo, A. I. Abushouk, M. Adabi, T. Adair, O. M. Adebayo, I. A. Adedeji, V. Adekanmbi, A. M. Adeoye, O. O. Adetokunboh, S. M. Advani, A. Afshin, M. Aghaali, A. Agrawal, K. Ahmadi, H. Ahmadieh, M. B. Ahmed, Z. Al-Aly, K. Alam, T. Alam, F. M. Alanezi, T. M. Alanzi, Lancet 2020, 396, 1160.
-
- Q. Ren, S. Sun, X.-D. Zhang, Nano Res. 2021, 14, 2535.
-
- T. Nakayama, S. Kuribayashi, T. Iwawaki, J. Hirato, R. Akai, Y. Fukai, H. Tanaka, T. Tomizawa, Y. Hashimoto, M. Kusano, T. Uraoka, Gastroenterology 2021, 160, S-535.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical